Business
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. The ICC Tribunal’s decision confirms Ipsen’s full rights to its clinical stage toxin programs in the aesthetic field. “This decisive ICC ruling supports Ipsen’s leadership pos
About this update from Ipsen Sa
[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/89RavcsKEHEdDt270X336Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"text","content":"PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. The ICC Tribunal’s decision confirms Ipsen’s full rights to its clinical stage toxin programs in the aesthetic field.","length":451,"tagName":"p"},{"type":"text","content":"“This decisive ICC ruling supports Ipsen’s leadership position in neuroscience research and development. We continue to assess all options to maximize the value of IPN10200,” said David Loew, CEO, Ipsen.","length":203,"tagName":"p"},{"type":"text","content":"About IPN10200 ","length":14,"tagName":"p"},{"type":"text","content":"IPN10200 is Ipsen’s first-in-class recombinant molecule, uniquely engineered to combine active sequence part A and binding sequence part B. Designed for enhanced receptor affinity and internalization, IPN10200 delivered a longer and clinically significant duration of effect. The molecule has been optimized for safety and efficacy and is being evaluated across four Phase II trials in both aesthetic and therapeutic indications.","length":429,"tagName":"p"},{"type":"text","content":"About LANTIC","length":12,"tagName":"p"},{"type":"text","content":"LANTIC (n=727) a Phase I/II trial evaluating the safety and efficacy of IPN10200 in three aesthetic indications of moderate to severe upper facial lines: glabellar lines, forehead lines and lateral canthal lines, across 3 Stages. Stage 1 includes patients evaluating safety and efficacy of IPN10200 in a dose finding and dose escalation stage in glabellar lines, with three defined steps including multiple doses of IPN10200; dose-escalation (step 1: Phase Ib), dose...